1. Home
  2. OIS vs PRME Comparison

OIS vs PRME Comparison

Compare OIS & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oil States International Inc.

OIS

Oil States International Inc.

HOLD

Current Price

$8.67

Market Cap

552.6M

Sector

Industrials

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.64

Market Cap

553.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OIS
PRME
Founded
1995
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
552.6M
553.2M
IPO Year
2000
2022

Fundamental Metrics

Financial Performance
Metric
OIS
PRME
Price
$8.67
$3.64
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$14.00
$7.56
AVG Volume (30 Days)
611.2K
2.6M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.18
EPS
0.12
N/A
Revenue
$1,088,133,000.00
$4,632,000.00
Revenue This Year
$3.12
$7.06
Revenue Next Year
$5.89
$47.01
P/E Ratio
$69.08
N/A
Revenue Growth
62.26
55.28
52 Week Low
$5.40
$2.67
52 Week High
$14.50
$6.94

Technical Indicators

Market Signals
Indicator
OIS
PRME
Relative Strength Index (RSI) 52.55 57.95
Support Level $8.60 $3.16
Resistance Level $8.86 $3.68
Average True Range (ATR) 0.36 0.23
MACD -0.04 0.06
Stochastic Oscillator 50.43 86.11

Price Performance

Historical Comparison
OIS
PRME

About OIS Oil States International Inc.

Oil States International Inc is a provider of manufactured products and services to customers in the energy, military and industrial sectors. The company operates through three business segments - Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. Its customers include many national oil and natural gas companies, and independent oil and natural gas companies, offshore drilling companies and other oilfield service, defense and industrial companies.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: